Single-Dose Pharmacokinetics of BMS-790052 in Subjects With Hepatic Impairment Compared to Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2015
At a glance
- Drugs Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 07 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Jul 2009 Planned end date changed from 1 Sep 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.